Epitan plans AIM listing
Thursday, 31 March, 2005
Melbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
The company said its London flotation would raise money to fund further development of Melanotan and increase its international profile. EpiTan is already listed on the Australian stock exchange.
"I am delighted to be able to introduce EpiTan to UK investors, particularly as we expect Europe to be a key market for our lead development product, Melanotan," said chief executive Iain Kirkwood.
Trading in the shares on AIM is due to begin in May. Investment bank Teather & Greenwood is the broker and adviser on the flotation.
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
